



Company Contact:

Richard Gabriel
President and CEO
941-366-3400

-or-

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

DNAPRINT GENOMICS CHAIRMAN HECTOR J. GOMEZ TO PRESENT AT NYSSA BIOTECH/PHARMA CONFERENCE WEDNESDAY, DEC. 14, 2:20 P.M.

SARASOTA, Fla., Dec. 7, 2005 -- DNAPrint™ genomics, Inc. (OTC BB: DNAG) announced today that Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., will be presenting at the 2005 Biotech/Specialty Pharma Industry Conference sponsored by The New York Society of Security Analysts (NYSSA) on Wednesday, December 14, at The Harvard Club, 27 W. 44th St., in New York City, at 2:20 p.m. Eastern time.

Dr. Gomez will provide an overview of DNAPrint Pharmaceuticals, Inc. a subsidiary of DNAPrint genomics, including the activities in the field of pharmacogenomics and the growing field of personalized medicine. Specifically, he will focus on “theranostic” test/drug combinations designed to maximize efficacy and minimize side effects by tailoring medications to specific individuals.

Dr. Gomez’ presentation will be available by means of a live Web cast that can be accessed on the Company’s Web site at www.dnাপrint.com or at <http://www.shareholder.com/DNAPrint/medialist.cfm>. The Web cast, which includes a PowerPoint presentation, will also be archived.

Those wishing to attend Dr. Gomez’s presentation can register on The New York Society of Security Analysts, Inc., Web site at http://www.nyssa.org/series/source/Meetings/ibomeetregister.cfm?PRODUCT_MAJOR=BIOTECH05

About DNAPrint

DNAPrint genomics, Inc. (www.dnাপrint.com), through its DNAPrint Pharmaceuticals, Inc., wholly owned subsidiary, is a developer of genomics-based products and services focused on drug development, computational biology and pharmacogenomic diagnostic tests. Computational biology and pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company’s first theranostic product (drug/test combination) is PT-401, a “Super EPO” (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint also develops and markets products for the law enforcement forensics and consumer markets that include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###